EPIC US Feasibility Study: Use of the FiberNet® Emboli Protection Device in Carotid Artery Stenting
Evaluating the Use of the FiberNet® Emboli Protection Device in Carotid Artery Stenting: The EPIC US Feasibility Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Newport Beach, California, United States, 92658
- Hoag Hospital
-
-
Maryland
-
Takoma Park, Maryland, United States, 20912
- Washington Adventist Hospital
-
-
Ohio
-
Columbus, Ohio, United States, 43214
- Riverside Methodist Hospital
-
-
South Dakota
-
Sioux Falls, South Dakota, United States, 57108
- North Central Heart Institue
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- One or more of the high surgical risk criteria.
- Candidate for percutaneous stenting with target lesion located within common or internal carotid artery.
- Symptomatic with atherosclerotic stenosis ≥ 50% or asymptomatic with atherosclerotic stenosis ≥ 70% of the carotid artery by NASCET Criteria.
Exclusion Criteria:
- Allergy to Heparin.
- Myocardial infarction within the last 14 days.
- Angioplasty or PTCA/PTA procedure within the past 48 hours.
- Cardiac surgery within the past 60 days.
- Planned invasive surgical procedure within 30 days.
- Stroke within the past 14 days.
- Transient ischemic neurological attack (TIA) or amaurosis fugax within the past 48 hours.
- Intracranial stenosis that exceeded the severity of an extracranial stenosis.
- Peripheral vascular disease of sufficient severity to prevent vascular access to the target lesion.
- Total occlusion of the target vessel.
- Lesion within 2cm of the ostium of the common carotid artery.
A stenosis that is known to be unsuitable for stenting because of one or more of:
- Tortuous or calcified anatomy proximal or distal to the stenosis
- Presence of visual thrombus
- Pseudo occlusion ('string sign')
- Serial lesions that requires more then one stent to cover entire lesion.
- Procedural complication prior to introduction of the FiberNet device into the body.
Study Plan
How is the study designed?
Design Details
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
The rate of all death, all stroke and myocardial infarction within 30 days of the procedure.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
All death and all stroke rates; Non-stroke neurological event rates; Technical success rates; Procedural success rates; Access site complication rates
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: J. Michael Bacharach, MD, North Central Heart Institute
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 864
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.